This product is specifically developed for the large-scale production of AAV in suspension systems. It is an optimized and modified linear polyethylenimine (Polyethylenimine Linear, PEI). The product is synthesized purely through chemical processes, free from animal-derived components, and has low cytotoxicity. It also offers broad applicability across various AAV serotypes. With high DNA loading capacity, a low transfection complex ratio, and high complex stability, this product facilitates large-scale AAV production.

The product is manufactured in accordance with GMP requirements and is provided in the form of a sterile liquid.

Features

Half Reagent Usage, Lower Costs

UltraAAV Transfection Reagent is specially developed for the large-scale production of recombinant AAV using suspension 293 cell lines. Its core advantage lies in cutting the required transfection reagent volume in half while maintaining consistent viral yield, alongside achieving a higher full-capsid ratio that facilitates downstream impurity removal. This feature not only significantly reduces production costs but also provides a more economical and efficient solution for large-scale AAV preparation. In practical applications, the UltraAAV Transfection Reagent effectively controls manufacturing costs by reducing the amount of reagent needed. For instance, when producing AAV in suspension 293F cells, the viral yield remains unaffected even when the reagent dosage is reduced by half.

Efficient Transfection, Broad Applicability

The UltraAAV Transfection Reagent not only offers significant advantages in dosage efficiency, but its transfection performance also far surpasses traditional reagents. Compared to PEI and other competing products, it demonstrates exceptionally high transfection efficiency when producing multiple serotypes—such as AAV2, AAV5, AAV8, and AAV9—in suspension 293F cells, delivering viral yields significantly higher than those of competitors.

Furthermore, the complex volume of this transfection reagent has been optimized to as low as 1%. This feature greatly facilitates the large-scale production of AAV viral vectors, overcoming the challenges posed by volume limitations in traditional manufacturing processes.

GMP Manufacturing and DMF Filing to Support Regulatory Submissions

UltraAAV Transfection Reagent strictly adheres to GMP manufacturing standards to ensure product quality and consistency. Hieff Trans® UltraAAV Transfection Reagent-GMP has completed its DMF (Drug Master File) filing.

Applications

Production of AAV Viral Vectors

Specifications

Components

Figures

Multi-Project Validation

Figure 1. AAV multi-project validation.
Hieff Trans™ UltraAAV yielded superior titers across AAV2, AAV5, AAV8, and AAV9 compared to leading PEIs. AAVs were produced in suspension 293F cells (1 µg DNA/10⁶ cells) and harvested at 72 h.

AAV9 Project Validation

Figure 2. Comparison of AAV9 packaging efficiency.
UltraAAV showed higher AAV9 packaging efficiency and genome titers than supplier P at both 1:0.5 and 1:1 ratios, with optimal yield at 1:0.5.

Same Yield, 50% Less Reagent

Strong Stability

Figure 3. Stability evaluation in the AAV9 project.
Hieff Trans™ demonstrated consistent performance across three GMP-grade batches and passed both accelerated and transport stability testing, ensuring reliable and stable supply.